The CancerGene web site is extremely useful. As Eureka notes:
This new data release brings the amount of freely available,
open-access data on the website to 453 cancer treatment compounds, 989
cancer cell lines, 494,973 genomic associations tested and 386,293 drug
dose response curves. The previous study has already enabled discoveries that led to drug
trials of PARP inhibitors in childhood bone cancer, directly contributed
to drug development in the pharmaceutical industry and powered 70
research studies across the globe. The datasets are accessed by over 350
users each day and this is set to increase with the new data release.
The project team hope that this enhanced resource will help to power new
discoveries and therapeutic options for many years to come. The Genomics of Drug Sensitivity in Cancer project is a pioneering
public-private partnership funded by Wellcome. It combines samples of
hospital patients' cancer cell lines with licensed and experimental
cancer drugs from a number of pharmaceutical companies, and applies
in-depth observation and genetic analysis to identify how the underlying
changes in a person's DNA affect how they will respond to treatment.
The ultimate goal is to identify biomarkers that could be used in the
clinic to identify which drugs will work best to treat a patient's
cancer, based on the tumour's genetic profile.
This definitely worth a look.